摘要
目的探讨胸腔积液HER-2蛋白检测对非小细胞肺癌(NSCLC)所致恶性胸腔积液的诊断价值。方法分别应用酶联免疫吸附法和应用免疫组织化学方法(SP法)检测20例NSCLC所致恶性胸腔积液中HER-2蛋白水平和胸液沉渣细胞HER-2蛋白的表达,同期取20例良性胸腔积液作对照。结果NSCLC所致恶性胸腔积液患者胸液中HER-2水平(6.18±2.35)ng/ml显著高于结核性胸腔积液患者(3.06±1.18)ng/ml(P<0.01),肺癌性胸液患者血清HER-2水平(3.89±1.98)ng/ml也显著高于结核组患者(2.31±0.65)ng/ml(P<0.05);20例NSCLC所致恶性胸液沉渣细胞HER-2蛋白阳性率(85.0%)与20例良性胸液细胞HER-2蛋白检测率(0%)具有统计学差异(P<0.01)。结论用酶联免疫吸附法和免疫组织化学方法(SP法)检测胸腔积液HER-2蛋白,对NSCLC所致恶性胸腔积液诊断具有重要的临床价值。
Objective To investigate clinical evaluation of HER-2 protein in malignant pleural effusion-associated non-small-cell lung cancer. Methods The enzyme linked immunosorbent assay and the immunohistochemical method （SP） were used to study HER-2 proteins in pleural effusion from 20 cases with non-small cell lung cancer. Twenty cases with benign pleural effusion were controlled. Resuits HER-2 levels in the pleural effusion were （6. 18±2.35 ）ng/ml significantly higher in the patients with malignant pleural effusion-associated non-small-cell lung cancer than （3.06±1.18） ng/ml in the patients with benign disease （P 〈0. 01 ）, HER-2 levels in the serum were （3.89±1.98ng/ml） significantly higher in the patients with malignant pleural effusion than （ 2.31 ± 0. 65 ） ng/ml in the patients with benign disease （ P 〈 0. 05 ）. The positive rate of HER-2 proteins in pleural effusion cells from 20 cases with non-small cell lung cancer was 85.0%. The positive rate of HER-2 proteins in pleural effusion cells from 20 cases with benign disease was 0%. There was significant difference between two groups （ P 〈 0. 01 ）. Conclusions The method of detection of HER-2 proteins in pleural effusion could provide important information for the diagnosis of non-small-cell lung cancer.
出处
《临床肺科杂志》
2008年第12期1625-1626,共2页
Journal of Clinical Pulmonary Medicine
